Hologic showcases new Mammosite at ASTRO 2009

Article

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting.

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting. The multi-lumen configuration, cleared by the FDA on August 27, allows oncologists to shape the radiation dose. It is the latest enhancement of the basic design, commercially launched some seven years ago. MammoSite delivers targeted radiation therapy directly to the area where cancer is most likely to recur. A full course of radiation can be delivered in just five days. The approach minimizes radiation exposure of healthy tissue surrounding the target site, minimizing side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.